1. Home
  2. BWB vs CTNM Comparison

BWB vs CTNM Comparison

Compare BWB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgewater Bancshares Inc.

BWB

Bridgewater Bancshares Inc.

HOLD

Current Price

$21.44

Market Cap

571.1M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.49

Market Cap

550.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWB
CTNM
Founded
2005
2009
Country
United States
United States
Employees
355
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
571.1M
550.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
BWB
CTNM
Price
$21.44
$14.49
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$21.67
$19.00
AVG Volume (30 Days)
175.9K
233.3K
Earning Date
04-21-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.57
N/A
Revenue Next Year
$12.35
N/A
P/E Ratio
$12.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.35
$6.23
52 Week High
$22.59
$16.91

Technical Indicators

Market Signals
Indicator
BWB
CTNM
Relative Strength Index (RSI) 55.43 48.86
Support Level $20.79 $13.23
Resistance Level $21.91 $15.52
Average True Range (ATR) 0.60 1.15
MACD 0.00 -0.03
Stochastic Oscillator 82.32 37.21

Price Performance

Historical Comparison
BWB
CTNM

About BWB Bridgewater Bancshares Inc.

Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: